(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Lexeo Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LXEO's revenue for 2025 to be $243,005,463, with the lowest LXEO revenue forecast at $243,005,463, and the highest LXEO revenue forecast at $243,005,463. On average, 1 Wall Street analysts forecast LXEO's revenue for 2028 to be $3,888,087,408, with the lowest LXEO revenue forecast at $3,888,087,408, and the highest LXEO revenue forecast at $3,888,087,408.
In 2029, LXEO is forecast to generate $17,355,990,180 in revenue, with the lowest revenue forecast at $17,355,990,180 and the highest revenue forecast at $17,355,990,180.